CENTOGENE Reports Third-Quarter 2020 Financial Results and Increases Full Year Guidance
CENTOGENE Reports Third-Quarter 2020 Financial Results and Increases Full Year Guidance
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 16, 2020 Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today provided an update on its corporate progress and reported its financial results for the three and nine months ended September 30, 2020.
Revenues increased 212% compared to Q3 2019, driven by the continued expansion of our COVID-19 testing offering
Increased 2020 full-year revenue guidance to more than €100 million
CENTOGENE Announces Voting Results of Extraordinary General Meeting
CENTOGENE Announces Voting Results of Extraordinary General Meeting
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 18, 2020 Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, today announced the voting results of the Company’s Extraordinary General Meeting. The shareholders of the Company voted in favor of all proposals, which included the appointments of Dr. Andrin Oswald as Managing Director and Dr. Jonathan Sheldon as Supervisory Director, the reappointment of Mr. Richard Stoffelen as Managing Director, and adjustments to the compensation of the Supervisory Board.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
CENTOGENE Reports Third-Quarter 2020 Financial Results and Increases Full Year Guidance
CENTOGENE GmbHDecember 16, 2020 GMT
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 16, 2020 (GLOBE NEWSWIRE) Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today provided an update on its corporate progress and reported its financial results for the three and nine months ended September 30, 2020.
Revenues increased 212% compared to Q3 2019, driven by the continued expansion of our COVID-19 testing offering